Active Systemic Lupus Erythematosus clinical trials

Explore recruiting active systemic lupus erythematosus clinical trials.

Recruiting active systemic lupus erythematosus studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Active Systemic Lupus Erythematosus trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety, tolerability, pharmacokinetics and pharmacodynamics of orally administered GLPG3667 in adult subjects with active systemic lupus erythematosus.

Germany, France, Spain, Poland, Bulgaria, Hungary

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-Controlled, Study to Evaluate the Efficacy and Safety of Afimetoran in Participants with Active Systemic Lupus Erythematosus.

Romania, Ireland, Spain, Germany, France, Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

A randomized, double-blind, placebo-controlled extension study to assess the long-term safety and tolerability of ianalumab in patients with systemic lupus erythematosus (SIRIUS-SLE extension)

Romania, Poland, Hungary, Portugal, Italy, Slovakia +5 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A multicenter, randomized clinical trial comparing the efficacy and safety of certolizumab pegol and belimumab in patients with moderate or severe activity of systemic lupus erythematosus (CERT-SLE)

Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Litifilimab (BIIB059) in Adult Participants With Active Systemic Lupus Erythematosus Receiving Background Nonbiologic Lupus Standard of Care

Romania, Germany, Hungary, Netherlands, Czechia, Belgium +1 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Litifilimab (BIIB059) in Adult Participants With Active Systemic Lupus Erythematosus Receiving Background Nonbiologic Lupus Standard of Care

France, Sweden, Bulgaria, Poland, Greece, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

Active Systemic Lupus Erythematosus trials by city

Active Systemic Lupus Erythematosus in Toronto Active Systemic Lupus Erythematosus in Vancouver Active Systemic Lupus Erythematosus in Montreal Active Systemic Lupus Erythematosus in Calgary Active Systemic Lupus Erythematosus in Edmonton Active Systemic Lupus Erythematosus in Ottawa Active Systemic Lupus Erythematosus in Winnipeg Active Systemic Lupus Erythematosus in Quebec City Active Systemic Lupus Erythematosus in Hamilton Active Systemic Lupus Erythematosus in Kitchener Active Systemic Lupus Erythematosus in London Active Systemic Lupus Erythematosus in Halifax Active Systemic Lupus Erythematosus in New York Active Systemic Lupus Erythematosus in Los Angeles Active Systemic Lupus Erythematosus in Chicago Active Systemic Lupus Erythematosus in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease